MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

Home・Akciju saraksts・Zai Lab Ltd ADR

Zai Lab Ltd ADR

Slēgts

SektorsVeselības aprūpe

20.33 0.54

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

20.22

Max

20.48

Galvenie mērījumi
By Trading Economics
Ienākumi	-14M -50M
Pārdošana	12M 128M
Peļņas marža	-39.506
Darbinieki	1,784
EBITDA	-17M -48M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+71.34% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 7. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-194M 2B
Iepriekšējā atvēršanas cena	19.79
Iepriekšējā slēgšanas cena	20.33

Ziņu noskaņojums

By Acuity

55%

45%

286 / 349 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

28.13 / 31.12 Atbalsts un pretestība

Zai Lab Ltd ADR Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 3. apr. 04:27 UTC

Galvenie ziņu notikumi

Singapore PM Warns That Fallout From Mideast War Could Outlast Conflict

2026. g. 3. apr. 20:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 3. apr. 18:30 UTC

Galvenie ziņu notikumi

An F15-E Just Went Down in Iran. What to Know About the $30 Million Jet. -- Barrons.com

2026. g. 3. apr. 18:14 UTC

Tirgus saruna

Eli Lilly Seen as Possible GLP-1 Leader With New Pill Approval -- Market Talk

2026. g. 3. apr. 17:50 UTC

Tirgus saruna

Microsoft's AI Development Will Weigh on Near-Term Azure Growth -- Market Talk

2026. g. 3. apr. 17:44 UTC

Iegādes, apvienošanās, pārņemšana

SBA Stock Just Had a Big Day. Why It's Suddenly Hot. -- Barrons.com

2026. g. 3. apr. 16:50 UTC

Galvenie ziņu notikumi

An F15-E Just Went Down in Iran. What to Know About the $90 Million Jet. -- Barrons.com

2026. g. 3. apr. 16:20 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 3. apr. 16:12 UTC

Peļņas

Oil Stocks Look Tapped Out. Why It's Time to Move Into Other Sectors. -- Barrons.com

2026. g. 3. apr. 15:56 UTC

Tirgus saruna

Galvenie ziņu notikumi

Crypto Markets May Be Active Over Holiday Weekend -- Market Talk

2026. g. 3. apr. 15:56 UTC

Tirgus saruna

Galvenie ziņu notikumi

Global Equities Roundup: Market Talk

2026. g. 3. apr. 15:56 UTC

Tirgus saruna

Galvenie ziņu notikumi

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 3. apr. 15:20 UTC

Galvenie ziņu notikumi

Berkshire, Travelers Join U.S. Plan to Insure Shippers in the Hormuz Strait -- Barrons.com

2026. g. 3. apr. 15:08 UTC

Iegādes, apvienošanās, pārņemšana

OpenAI Makes Surprise Media Acquisition Ahead of IPO. Why It Will Fail. -- Barrons.com

2026. g. 3. apr. 14:11 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Shock From War in Iran May Show Up In 2Q Job Growth Data -- Market Talk

2026. g. 3. apr. 12:56 UTC

Tirgus saruna

Treasury Yields, Dollar Higher Following Robust March Hiring -- Market Talk

2026. g. 3. apr. 08:20 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 3. apr. 08:01 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 3. apr. 08:01 UTC

Tirgus saruna

Meituan's Profitability Likely to Improve This Year -- Market Talk

2026. g. 3. apr. 07:45 UTC

Tirgus saruna

LG Electronics Could Post Above-Consensus 1Q Earnings -- Market Talk

2026. g. 3. apr. 06:17 UTC

Tirgus saruna

Naver Likely to Post Below-Consensus 1Q Earnings -- Market Talk

2026. g. 3. apr. 06:17 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 3. apr. 04:33 UTC

Tirgus saruna

China Merchants Port Earnings Likely to Recover This Year -- Market Talk

2026. g. 3. apr. 04:33 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 3. apr. 04:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 3. apr. 04:01 UTC

Tirgus saruna

Posco Holdings 1Q Earnings Could Fall Short of Expectations -- Market Talk

2026. g. 3. apr. 02:01 UTC

Tirgus saruna

India Consumer-Staple Companies Likely to Post Broadly Steady 4Q Results -- Market Talk

2026. g. 3. apr. 01:59 UTC

Tirgus saruna

Sea's Shopee E-Commerce Platform Likely in Reinvestment Phase -- Market Talk

2026. g. 3. apr. 01:44 UTC

Tirgus saruna

Samsung Likely to Report Record Quarterly Earnings in 2026 -- Market Talk

2026. g. 3. apr. 01:22 UTC

Tirgus saruna

Dollar Could Hit 160 Yen in Thin Holiday Trading -- Market Talk

Salīdzinājums

Cenas izmaiņa

Zai Lab Ltd ADR Prognoze

Cenas mērķis

By TipRanks

71.34% augšup

Prognoze 12 mēnešiem

Vidējais 34.97 USD 71.34%

Augstākais 47 USD

Zemākais 21.8 USD

Pamatojoties uz 6 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Zai Lab Ltd ADR — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

6 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 6 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Zai Lab Ltd ADR — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

28.13 / 31.12Atbalsts un pretestība

Recent bearish events outweigh bullish events.

All events are bullish.

Noskaņojums

By Acuity

286 / 349 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.